Tenaya Therapeutics(US:TNYA) Globenewswireยท2025-11-04 22:30Core Insights - Tenaya Therapeutics is set to present interim safety and efficacy results from the MyPEAK-1 Phase 1b/2a clinical trial for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy, at the AHA 2025 Scientific Sessions [1][2] - The company will also showcase results from a preclinical study on cellular reprogramming gene therapy in a pig model of ischemic heart failure [1][2] Company Overview - Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing potentially curative therapies for heart disease [4] - The company's pipeline includes TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy [4][5] - Tenaya employs integrated capabilities such as target validation and capsid engineering to develop novel medicines based on genetic insights [5] Upcoming Events - The AHA presentation will occur on November 8, 2025, featuring Dr. Milind Y Desai as the presenting author [2] - A second presentation on cellular reprogramming will take place on November 9, 2025, led by Kathy Ivey [2] - Tenaya management will host a conference call on November 10, 2025, to discuss the TN-201 data presented at the AHA sessions [3]